Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Differential Response to Sorafenib Administration for Advanced Hepatocellular Carcinoma.
Biomedicines. 2022 Sep 14;10(9):2277. doi: 10.3390/biomedicines10092277.
Biomedicines. 2022.
PMID: 36140381
Free PMC article.
Dynamic Change of Albumin-Bilirubin Score Is Good Predictive Parameter for Prognosis in Chronic Hepatitis C-hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization.
Lin PT, Teng W, Jeng WJ, Chen WT, Hsieh YC, Huang CH, Lui KW, Hung CF, Wang CT, Chai PM, Lin CC, Lin CY, Lin SM, Sheen IS.
Lin PT, et al. Among authors: chai pm.
Diagnostics (Basel). 2022 Mar 9;12(3):665. doi: 10.3390/diagnostics12030665.
Diagnostics (Basel). 2022.
PMID: 35328217
Free PMC article.
Item in Clipboard
Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
Teng W, Lin CC, Su CW, Lin PT, Hsieh YC, Chen WT, Ho MM, Wang CT, Chai PM, Hsieh JC, Lin CY, Lin SM.
Teng W, et al. Among authors: chai pm.
Am J Cancer Res. 2022 Apr 15;12(4):1899-1911. eCollection 2022.
Am J Cancer Res. 2022.
PMID: 35530282
Free PMC article.
Item in Clipboard
Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first-line treatment for unresectable hepatocellular carcinoma.
Su CW, Teng W, Lin PT, Jeng WJ, Chen KA, Hsieh YC, Chen WT, Ho MM, Hsieh CH, Wang CT, Chai PM, Lin CC, Lin CY, Lin SM.
Su CW, et al. Among authors: chai pm.
Cancer Med. 2023 Mar;12(6):7077-7089. doi: 10.1002/cam4.5506. Epub 2022 Dec 5.
Cancer Med. 2023.
PMID: 36468578
Free PMC article.
Item in Clipboard
Significance of Physical Status and Liver Function Reserve for Outcome of Patients with Advanced Hepatocellular Carcinoma Receiving Lenvatinib Treatment.
Chan KM, Lai Y, Hung HC, Lee JC, Cheng CH, Wang YC, Wu TH, Lee CF, Wu TJ, Chou HS, Wang CT, Chai PM, Lien HY, Lee WC.
Chan KM, et al. Among authors: chai pm.
J Hepatocell Carcinoma. 2023 Feb 18;10:281-290. doi: 10.2147/JHC.S393964. eCollection 2023.
J Hepatocell Carcinoma. 2023.
PMID: 36845025
Free PMC article.
Item in Clipboard
Concurrent Atezolizumab Plus Bevacizumab and High-Dose External Beam Radiotherapy for Highly Advanced Hepatocellular Carcinoma.
Su CW, Teng W, Shen EY, Huang BS, Lin PT, Hou MM, Wu TH, Tsan DL, Hsieh CH, Wang CT, Chai PM, Lin CY, Lin SM, Lin CC.
Su CW, et al. Among authors: chai pm.
Oncologist. 2024 Mar 26:oyae048. doi: 10.1093/oncolo/oyae048. Online ahead of print.
Oncologist. 2024.
PMID: 38530254
Free article.
Item in Clipboard
Locoregional treatment improves overall survival for liver cancer during second-line regorafenib or immune checkpoint inhibitor.
Lin PT, Hsu YC, Kao YT, Teng W, Hsieh YC, Chen WT, Su CW, Wang CT, Chai PM, Lin CC, Lin CY, Lin SM.
Lin PT, et al. Among authors: chai pm.
Am J Cancer Res. 2024 Mar 15;14(3):1306-1315. doi: 10.62347/GFVP1262. eCollection 2024.
Am J Cancer Res. 2024.
PMID: 38590407
Free PMC article.
Item in Clipboard
Cite
Cite